elranatamab Elrexfio
Selected indexed studies
- ** (, 2024) [PMID:39693464]
- Elranatamab: First Approval. (Drugs, 2023) [PMID:37924427]
- ** (, 2024) [PMID:39088667]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Elranatamab: First Approval. (2023) pubmed
- Elranatamab. (2006) pubmed
- Linvoseltamab (Lynozyfic) for multiple myeloma. (2025) pubmed
- Antibodies to watch in 2024. (2024) pubmed
- PMID:39693464 (2024) pubmed
- PMID:39088667 (2024) pubmed
- Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma. (2023) pubmed
- Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma. (2025) pubmed
- Elranatamab: Mechanism of Action, Clinical, and Translational Science. (2026) pubmed
- An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions. (2026) pubmed